Live Cell Beating Assay Using Human iPSC-derived Cardiomyocytes for Evaluation of Drug Efficacy and Toxicity

Poster   Oct 05, 2011

 
Live Cell Beating Assay Using Human iPSC-derived Cardiomyocytes for Evaluation of Drug Efficacy and Toxicity
 
View Poster
 
 

Oksana Sirenko, Carole Crittenden, Blake Anson, Jayne Hesley, Yen-Wen Chen, Nick Callamaras and Evan F. Cromwell

 
 

This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License

 
View Poster
 

This content appears on:

Cell Science Drug Discovery

To personalize the content you see on Technology Networks, Log In or Join Today

Login Join
 
 

OTHER POSTERS

Applications of chemically modified synthetic guide RNA for CRISPR-Cas9 genome editing

Poster

Our results indicate that MS modifications are required for experiments with co-electroporation of Cas9 mRNA and synthetic gRNA, yet have no impact on editing efficiency when delivered with lipid-based transfection reagents.

READ MORE

Novel lead optimization strategy of BACE I inhibitors for the treatment of Alzheimer’s disease by Quantitative Structure-Activity Relationship (QSAR) and Physiologically-Based Pharmacokinetics (PBPK) modeling

Poster

In this study, we introduce an innovative in silico-based high throughput lead optimization strategy with QSAR and PBPK modelings using StarDrop™, ADMET predictor® and GastroPlus®.

READ MORE

Use of Non-modified RNAs for the Derivation of Clinically-relevant iPS Cell Lines from Human Blood, Urine and Skin Cells using GMP-compliant Reagents

Poster

We have developed protocols using our StemRNA-NM Reprogramming Kit for generating iPS cells from skin-derived fibroblasts, blood-derived EPCs, and urine-derived UDCs using GMP-compatible reagents (NutriStem medium, iMatrix-511 recombinant laminin). These protocols generate GMP-compatible stem cells without the use of feeders, conditioned medium, additional small molecules or proteins, or passaging during reprogramming.

READ MORE

 

Comments | 0 ADD COMMENT